Rothemberg, M.L.; Nelson, R.; Hande, K.R. New drugs on the horizon: Matrix MetalloproteinaseInhibitors. Stem. Cells 1999, 17, 237–240. [ Google Scholar] [ CrossRef] [ PubMed] Pournourmohammadi, S.; Grimaldi, M.; Stridh, M.H.; Lavallard, V.; Waagepetersen, H.S.; Wollheim, C.B.; Maechler, P. Epigallocatechin-3–gallate (EGC) activates AMPK through the inhibition of glutamatedehydrogenase in muscle and pancreatic Bcells: A potential beneficial effect in the pre-diabetic state. Int. J. Biochem. Cell Biol. 2017, 88, 220–225. [ Google Scholar] [ CrossRef][ Green Version]

Considering the highly disappointing results from the TAILORX breast cancer study (specifically 85% of women with early breast cancer ( those with an identifiable genetic signature) received no benefited from traditional preventative treatments. How can metabolic therapies that have shown the success noted above now not be aggressively funded and researched?He has at least one dissent decree from the Virginia medical licensing board for violating 3 laws in relation illegal testing and practices. Klement, R.J. Wilhelm Brünings’ forgotten contribution to the metabolic treatment of cancer utilizing hypoglycemia and very low carbohydrate (ketogenic) diet. J. Tradit. Complement. Med. 2019, 9, 192–200. [ Google Scholar] [ CrossRef] As I watched the Pca spread in scans get worse, the number of bone mets has increased, and I have many little ones not making PsMa hence Lu177 or Ac225 won'k, but Ra may work, but mean extension of lifetime of Ra223 is 4 months, but then men seeking Ra223 have tried all other things and have very high Psa, maybe 600, or 10 times what mine is.

The Better Business Bureau has hundreds of complaints about double-billing and bad supplements from his health supplement store. Guy Tenenbaum is a youtuber that I’ve been following for the past 10 months but I’ve watched every video that he’s put out over the past 2 years to document his journey. Cassim, S.; Vučetić, M.; Ždralević, M.; Pouyssegur, J. Warburg and Beyond: The Power of Mitochondrial Metabolism to Collaborate or replace Fermentative Glycolysis in Cancer. Cancers 2020, 12, 1119. [ Google Scholar] [ CrossRef] [ PubMed] I truly believe the guy (no pun intended) is legit as he doesn’t sell anything and you see how his body has changed over the past two years (white hair became grey, went from heavy set to skinny, etc…) and he also makes all of his documents (MRI, Scans, etc…) available for all to view on Google Drive.

About

An early observation by Brünings, recalled by Klement [ 27], deserves to be mentioned. In his study, patients were given a low-carbohydrate diet, which was associated with an insulin injection protocol that aimed to decrease the supply of glucose to tumors. Initially he observed a decrease in tumor sizes, and later a rebound, while feeding patients with a high-fat diet. We now know that insulin elicits the release of somatostatin from delta cells, which decreases glucagon and ketogenesis leading to a probable decrease in BHB and growth of ketone-dependent tumors. However, since Brünings fed patients with a high-fat ketogenic diet, a rebound of tumors took place. Brünings was not aware that somatostatin release triggered by the insulin injections was probably behind the initial reduction in tumors [ 28]. Indeed, somatostatin decreases glucagon and ketogenesis at the beginning of the trial; however, a late rebound of tumors probably occurs when insulin fails to maintain somatostatin release. In time, the decline in somatostatin stops inhibiting glucagon, which then boosts ketogenesis, providing ketones to the tumor [ 29]. In an earlier work on animal cancer models, we observed that octreotide, a somatostatin analog, decreases tumor volumes [ 12]. This first article in the starve cancer series is quite instructive. I had no idea that glucose levels could be brought down to the levels reported in the article. I have seen the tumor responses to fairly modest reduction in glucose in mice models; one can only guess what might happen if glucose levels were brought down to the extent imagined in the article. Warburg, O. On the origin of cancer cell. Science 1956, 123, 309–314. [ Google Scholar] [ CrossRef] [ PubMed]